HTG Molecular Diagnostics Reports Second Quarter 2022 Results
Call scheduled for today, August 11, 2022, at 4:30 pm ET
TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022.
Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following:
- A webinar titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research” featuring Pete Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie, addressed how Dr. Ansell and his team at AbbVie have overcome many challenges they have previously faced using FFPE clinical samples by integrating the HTG Transcriptome Panel (HTP) into their biomarker strategies.
- In a keynote presentation at the 7th Annual Markets and Markets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials,” Chetan Deshpande, Director, Biomarker Clinical Assay Lead, Global Product Development at Pfizer discussed the challenges that are generally faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq technology in multiple clinical trials to overcome these challenges.
- The first peer-reviewed journal article featuring our HTP was published by one of the participants in our Early Adopter Program in Frontiers in Medicine less than one year after the commercial release of the product.
- The Company published a second white paper, further establishing the utility of its transcriptome-informed approach to drug design and discovery utilizing its proprietary HTG EdgeSeq technology.
- A webinar addressing "Drug Candidate Attrition - How to Improve Clinical Development Success and Patent Outcomes," including a presentation from key opinion leader, Dr. Robert Spitale, PhD, University of California - Irvine, further outlined the potential uses of RNA-based platform technologies in drug discovery.
In July 2022, the Company entered into an amendment to its June 24, 2020 Loan and Security Agreement (“LSA”) with its lender, Silicon Valley Bank. Under the terms of the amendment, Silicon Valley Bank agreed to waive the existing financial covenant through the remaining term of the LSA in exchange for a partial prepayment of outstanding principal. The remaining principal will continue to amortize through December 2023, the original maturity date of the term loan.
Second Quarter 2022 Financial Highlights:
Revenue for the quarter ended June 30, 2022 was $1.5 million, compared with $2.1 million for the same period in 2021, and was comprised entirely of product and product-related services revenue. Sales of the HTP to new and existing customers as consumables and sample processing services represented over 42% of revenue for the quarter ended June 30, 2022.
Net loss from operations for the quarter ended June 30, 2022 was $5.7 million, compared with $4.1 million for the same period in 2021. Net loss per share was $(0.54) for the quarter ended June 30, 2022 compared with $(0.39) for the second quarter of 2021.
Cash, cash equivalents and short-term available-for-sale securities totaled $14.1 million as of June 30, 2022, with current liabilities of approximately $10.2 million and non-current liabilities of $6.5 million.
Conference Call and Webcast:
HTG will host a conference call for the investment community today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details are as follows:
| Date: | Thursday, August 11, 2022 | ||
| Time: | 4:30 p.m. Eastern Time | ||
| Toll Free: | (800) 954-0602 | ||
| International: | (212) 231-2936 | ||
| Conference ID: | 22019810 | ||
| Webcast: |
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit .
HTG Investor Contact:
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email:
-Financial tables follow-
| HTG Molecular Diagnostics, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Product and product-related services revenue | $ | 1,491,582 | $ | 2,074,204 | $ | 2,676,036 | $ | 3,509,350 | |||||||
| Operating expenses: | |||||||||||||||
| Cost of product and product-related services revenue | 1,014,469 | 971,043 | 1,869,517 | 1,756,243 | |||||||||||
| Selling, general and administrative | 4,306,916 | 3,903,815 | 8,969,927 | 7,763,434 | |||||||||||
| Research and development | 1,847,101 | 1,281,361 | 3,767,531 | 2,653,401 | |||||||||||
| Total operating expenses | 7,168,486 | 6,156,219 | 14,606,975 | 12,173,078 | |||||||||||
| Operating loss | (5,676,904 | ) | (4,082,015 | ) | (11,930,939 | ) | (8,663,728 | ) | |||||||
| Other income (expense) | (206,425 | ) | (252,469 | ) | (449,523 | ) | (516,614 | ) | |||||||
| Gain on forgiveness of PPP Loan | — | 1,735,792 | — | 1,735,792 | |||||||||||
| Net loss before income taxes | (5,883,329 | ) | (2,598,692 | ) | (12,380,462 | ) | (7,444,550 | ) | |||||||
| Provision for income taxes | (4,880 | ) | (16,260 | ) | (5,266 | ) | (18,709 | ) | |||||||
| Net loss | $ | (5,888,209 | ) | $ | (2,614,952 | ) | $ | (12,385,728 | ) | $ | (7,463,259 | ) | |||
| Net loss per share, basic and diluted | $ | (0.54 | ) | $ | (0.39 | ) | $ | (1.30 | ) | $ | (1.17 | ) | |||
| Shares used in computing net loss per share, basic and diluted | 11,002,456 | 6,687,330 | 9,515,376 | 6,365,827 | |||||||||||
| HTG Molecular Diagnostics, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| June 30, | December 31, | ||||||
| 2022 | 2021 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 5,756,578 | $ | 9,599,950 | |||
| Short-term investments available-for-sale, at fair value | 8,342,184 | 12,343,456 | |||||
| Accounts receivable, net | 1,259,093 | 2,092,466 | |||||
| Inventory, net | 1,955,922 | 1,987,753 | |||||
| Prepaid expenses and other | 2,011,072 | 1,163,339 | |||||
| Total current assets | 19,324,849 | 27,186,964 | |||||
| Operating lease right-of-use assets | 1,143,270 | 1,345,361 | |||||
| Property and equipment, net | 780,695 | 1,118,886 | |||||
| Other non-current assets | 956,655 | 809,476 | |||||
| Total assets | $ | 22,205,469 | $ | 30,460,687 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,119,452 | $ | 1,649,440 | |||
| Accrued liabilities | 1,334,287 | 2,022,569 | |||||
| Current portion of long-term debt | 6,614,817 | 5,167,586 | |||||
| NuvoGen obligation - current | 523,849 | 548,301 | |||||
| Operating lease liabilities - current | 429,200 | 413,865 | |||||
| Other current liabilities | 137,644 | 141,749 | |||||
| Total current liabilities | 10,159,249 | 9,943,510 | |||||
| NuvoGen obligation - non-current, net of discount | 3,646,858 | 3,900,880 | |||||
| Long-term debt, net | 2,023,579 | 5,178,629 | |||||
| Other non-current liabilities | 806,094 | 1,037,844 | |||||
| Total liabilities | 16,635,780 | 20,060,863 | |||||
| Commitments and Contingencies | |||||||
| Total stockholders’ equity | 5,569,689 | 10,399,824 | |||||
| Total liabilities and stockholders' equity | $ | 22,205,469 | $ | 30,460,687 | |||
